Voyager therapeutics, inc. (VYGR)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Collaboration revenue

18,067

32,674

20,433

46,087

5,197

2,008

2,094

2,575

942

6,346

1,148

1,177

1,464

2,362

3,308

3,720

4,830

4,937

4,937

4,884

2,576

Operating expenses:
Research and development

32,294

36,551

29,777

28,576

24,831

16,913

16,632

16,507

14,853

13,327

19,561

15,300

14,072

12,724

10,309

10,484

8,732

9,220

6,481

6,455

5,523

General and administrative

10,206

9,891

8,463

8,322

9,659

8,256

6,609

11,762

7,182

5,366

4,942

4,516

4,914

3,481

3,370

2,854

3,565

3,157

2,475

2,396

1,881

Total operating expenses

42,500

46,442

38,240

36,898

34,490

25,169

23,241

28,269

22,035

18,693

24,503

19,816

18,986

16,205

13,679

13,338

12,297

12,377

8,956

8,851

7,404

Operating loss

-24,433

-13,768

-17,807

9,189

-29,293

-23,161

-21,147

-25,694

-21,093

-12,347

-23,355

-18,639

-17,522

-13,843

-10,371

-9,618

-7,467

-7,440

-4,019

-3,967

-4,828

Other income:
Interest income

978

1,392

1,823

2,097

1,145

910

942

870

588

428

291

255

253

-1,093

1,171

433

465

-

102

73

-

Other (expense) income

-808

-198

978

-133

978

-281

-84

-717

399

122

-282

-297

395

617

-99

-150

-186

-

-

-

-

Total other income

170

1,194

2,801

1,964

2,123

629

858

153

987

550

9

-42

648

-476

1,072

283

279

-

102

-

-

Loss before income taxes

-

-

-15,006

11,153

-

-22,532

-20,289

-25,541

-20,106

-11,797

-23,346

-18,681

-16,874

-14,319

-9,299

-9,335

-7,188

-

-3,917

-

-

Income tax benefit

-

-

-

-

-

0

0

0

-180

-

0

195

-226

-

-303

-

-

-

-

-

-

Other financing expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

9,749

Total other expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-72

9,749

Net loss

-24,263

-12,574

-15,006

11,153

-27,170

-22,532

-20,289

-25,541

-19,926

-11,828

-23,346

-18,876

-16,648

-14,674

-8,996

-9,335

-7,188

-7,283

-3,917

-3,895

-14,577

Other comprehensive income
Net unrealized gain on available-for-sale-securities

525

-89

-116

176

58

41

-49

37

5

168

-485

-295

377

-682

570

30

281

-

58

-20

-

Cumulative effect adjustment resulting from ASU No. 2016-01

-

-

-

-

-

-

-

-

-20,050

-

-

-

-

-

-

-

-

-

-

-

-

Total other comprehensive income

525

-89

-116

176

58

-79

-49

37

125

168

-485

-295

377

-682

570

30

281

-

58

-20

-

Comprehensive loss

-23,738

-12,663

-15,122

11,329

-27,112

-22,611

-20,338

-25,504

-19,801

-11,660

-23,831

-19,171

-16,271

-15,356

-8,426

-9,305

-6,907

-7,572

-3,859

-3,915

-14,577

Net income (loss) per share, basic

-

-

-

0.30

-

-

-

-0.80

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per share, diluted

-

-

-

0.29

-

-

-

-0.80

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average common shares outstanding, basic

-

-

-

36,610

-

-

-

31,976

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average common shares outstanding, diluted

-

-

-

37,941

-

-

-

31,976

-

-

-

-

-

-

-

-

-

-

-

-

-

Reconciliation of net loss to net loss attributable to common stockholders:
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,328

2,594

2,452

999

Accrued dividends on series A preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

206

403

399

237

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,188

-8,817

-6,914

-6,746

-15,813

Net loss per share, basic and diluted

-0.66

-

-0.41

-

-0.81

-

-0.63

-

-0.63

-0.37

-0.89

-0.73

-0.65

-0.58

-0.35

-0.37

-0.29

36.12

-5.25

-5.94

-15.79

Weighted-average common shares outstanding, basic and diluted

36,963

-

36,742

-

33,353

-

32,191

-

31,759

29,312

26,164

25,946

25,791

25,530

25,374

25,228

25,076

13,311

1,317

1,135

1,001

ASU 2016-01
Cumulative effect adjustment resulting from ASU No. 2016-01

-

-

-

-

-

-

0

0

120

-

-

-

-

-

-

-

-

-

-

-

-